BMS-906024 is a drug with a benzodiazepine structure, developed by Bristol-Myers Squibb and disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat breast, lung, colon cancers and leukemia.[1] The drug works as a pan-Notch inhibitor. The structure is one of a set patented in 2012,[2] and is being studied in clinical trials.[3][4][5]
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
PubChem SID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C26H26F6N4O3 |
Molar mass | 556.509 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ Drahl C (2013). "Liveblogging First-Time Disclosures of Drug Structures from #ACSNOLA". Chemical and Engineering News. American Chemical Society.
- ^ WO 2012129353, Quesnelle C, Kim SH, Lee F, Gavai A, "Bisfluoroalkyl-1,4-Benzodiazepinone Compounds", published 27 September 2012, assigned to Bristol-Myers Squibb Company
- ^ Gavai AV, Quesnelle C, Norris D, Han WC, Gill P, Shan W, et al. (May 2015). "Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid Tumors". ACS Medicinal Chemistry Letters. 6 (5): 523–7. doi:10.1021/acsmedchemlett.5b00001. PMC 4434460. PMID 26005526.
- ^ Morgan KM, Fischer BS, Lee FY, Shah JJ, Bertino JR, Rosenfeld J, et al. (December 2017). "Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma". Molecular Cancer Therapeutics. 16 (12): 2759–2769. doi:10.1158/1535-7163.MCT-17-0439. PMC 5716926. PMID 28978720.
- ^ Sosa Iglesias V, Theys J, Groot AJ, Barbeau LM, Lemmens A, Yaromina A, et al. (2018). "Synergistic Effects of NOTCH/γ-Secretase Inhibition and Standard of Care Treatment Modalities in Non-small Cell Lung Cancer Cells". Frontiers in Oncology. 8: 460. doi:10.3389/fonc.2018.00460. PMC 6234899. PMID 30464927.